These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 17089782

  • 1. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
    Teva A, Porrozzi R, Oliveira-Neto MP, Grimaldi GJ.
    J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
    [Abstract] [Full Text] [Related]

  • 2. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB, Mendonça SC, Callahan H, Portal AC, Max G.
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T.
    Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E, Aguiar MG, Soares de Souza Lima B, Ferreira LA, Rabello A.
    J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
    [Abstract] [Full Text] [Related]

  • 8. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD.
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacies of two antimony regimens to treat Leishmania braziliensis-induced cutaneous Leishmaniasis in rhesus macaques (Macaca mulatta).
    Grimaldi G, Porrozzi R, Friedrich K, Teva A, Marchevsky RS, Vieira F, Miekeley N, Paumgartten FJ.
    Antimicrob Agents Chemother; 2010 Jan; 54(1):502-5. PubMed ID: 19822700
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [Abstract] [Full Text] [Related]

  • 12. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
    Zauli-Nascimento RC, Miguel DC, Yokoyama-Yasunaka JK, Pereira LI, Pelli de Oliveira MA, Ribeiro-Dias F, Dorta ML, Uliana SR.
    Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
    Pimentel MI, Baptista C, Rubin EF, Vasconcellos Ede C, Lyra MR, Salgueiro Mde M, Saheki MN, Rosalino CM, Madeira Mde F, Silva AF, Confort EM, Schubach Ade O.
    Rev Soc Bras Med Trop; 2011 Jan; 44(2):254-6. PubMed ID: 21552747
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
    Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, Berman JD.
    Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment.
    Robledo SM, Valencia AZ, Saravia NG.
    J Parasitol; 1999 Apr; 85(2):360-6. PubMed ID: 10219320
    [Abstract] [Full Text] [Related]

  • 18. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
    Perez-Franco JE, Cruz-Barrera ML, Robayo ML, Lopez MC, Daza CD, Bedoya A, Mariño ML, Saavedra CH, Echeverry MC.
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811
    [Abstract] [Full Text] [Related]

  • 19. Development of Leishmania (Viannia) panamensis lesions and relationship of numbers of amastigotes to lesion area on antimony-treated and untreated hamsters.
    Hanson WL, Chapman WL, Waits VB, Lovelace JK.
    J Parasitol; 1991 Oct; 77(5):780-3. PubMed ID: 1919929
    [Abstract] [Full Text] [Related]

  • 20. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.